(Date:11/21/2008)...swire-FirstCall/ -- The Providence Service,Corpor... A. Norris, the Company,s,Chief Operating Officer...rectors. Mr. Norris, appointment fills the vacanc... Geringer and returns the board to six members. M...Board. , Mr. Norris, age 41, has been with ...
(Date:11/21/2008)... a novel technique to combat cancer, study says,...- Belgian researchers have discovered that some ca...od, and this might lead to new treatments that sta...iferate, all cells in the body need to produce ene...ocess that requires oxygen. Compared with normal c...
(Date:11/21/2008)...Vigorously Protect Investment And Restore Sharehol...re-USNewswire/ -- Dr. Stephen Joffe, Craig Joffe, ...Schedule 13D with the U.S. Securities and Exchange...closing ownership of 11.4% of LCA-Vision, Inc. (Na...site laser vision correction centers in 33 states ...
(Date:11/21/2008)...wswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (N... overwhelmingly approved the proposals submitted t... Pharmaceuticals Industries Ltd. (Nasdaq: TEVA )...helming support of the transaction by the Barr sha...and CEO. "We are pleased with the progress that we...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4(Date:11/19/2008)...ers $5 Million Payment from Roche- , , MONT...ry Pharmaceuticals Corp. (Nasdaq: MEMY ) today a...for its Phase 2 trial of R3487/MEM 3454, its lead ...mpairment associated with schizophrenia (CIAS). T...e 2 trial, triggering a $5.0 million payment from ...
(Date:11/18/2008)... www.christmasseals.org to learn more, make a don...WASHINGTON, Nov. 17 Mil...s month, courtesy of the American Lung Association...nnual fundraising tradition dating back to 1907 wh...erculosis. , , "Most Americans alive toda...
(Date:11/18/2008)...WNE, Va., Nov. 18 Forty...ered at a November national forum to consider cutt...lic health and national economy from outbreaks of ...nced today. , , Among those innovations: ,... American kitchen table that detects highly contag...
(Date:11/18/2008)...ized study will enroll newly diagnosed, elderly AM...Newswire/ -- Celator Pharmaceuticals today announc...ndomized Phase 2 clinical study of CPX-351 (Cytara...with newly diagnosed acute myeloid leukemia (AML).... Feldman, MD at the Weill Medical College of Corn...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Life under the laser 4630 1Life under the laser 4630 2Baxa Corporation Named to Inc 5000 for Second Consecutive Year as One of the Fastest Growing Private Companies in the US 7375 1Baxa Corporation Named to Inc 5000 for Second Consecutive Year as One of the Fastest Growing Private Companies in the US 7375 2Journal of Nutrition Health and Aging to be published by Springer 4626 1Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL 28R 29 D Dimer Assay 7367 1Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL 28R 29 D Dimer Assay 7367 2... Substantial,Reduction of Disease Activity in Pati...rosis , Combination Treatment With Antibiotic Furt... KANSAS CITY, Mo, May 4, 2007 - New data from a ra...tion of Copaxone,(glatiramer acetate injection) al...1 Gadolinium (Gd)-enhancing lesions of the,brain b...
...n Multiple,Sclerosis May Include Direct Activity i... FTY720 stimulates cells,that may help reduce neur...ed by multiple sclerosis , · Separately, an... II clinical study found that the proportion of,pa...lower in the,FTY720 groups compared to placebo , &...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: